The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | A Phase II study of digital life coaching during stem cell transplantation for patients with myeloma
Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA, shares some insights into a Phase II study evaluating the impact of digital life coaching in patients with multiple myeloma undergoing stem cell transplantation (SCT; NCT04589286). Results demonstrated that digital life coaching improved physical quality of life (QoL) in patients, highlighting the value of this approach. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting/advisory: SparkCures, Sanofi Pasteur, Genentech/Roche, Janssen Oncology, Bristol-Myers Squibb/Celgene, Caribou Biosciences, Pfizer
Research funding: Pack Health
